About Qureight

Toby Maher is Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles.

Dr Maher has spent over 20 years specialising in the management of interstitial lung disease. Since June 2020 he has been Director of ILD at Keck Medicine of University of Southern California. He previously ran the ILD unit at Royal Brompton Hospital, London and was a Professor of ILD at Imperial College, London. His research interests include; biomarker discovery, cellular senescence in the pathogenesis of IPF and clinical trials. He has been involved in >100 trials in fibrotic lung disease from phase 1b through to phase 4 and including those assessing IPF, sarcoidosis, scleroderma, rheumatoid arthritis and inflammatory myositis. He is an associate editor for American Journal of Respiratory and Critical Care Medicine. He has authored over 400 papers on pulmonary fibrosis.

Phil is a Professor of Interstitial Lung Disease at Imperial College London and holds the Asthma + Lung UK Chair of Respiratory Research. He is a Consultant in Interstitial Lung Disease and Director of the NIHR Cardiorespiratory Clinical Research Facility at the Royal Brompton Hospital. He qualified from Guy’s, King’s and St Thomas’ School of Medicine in 2004, where he completed an intercalated BSc in Molecular Genetics. He trained at St Mary’s hospital as an NIHR academic clinical fellow in respiratory medicine and went on to undertake a PhD at Imperial College. Following completion of his clinical training in respiratory and critical care medicine he returned to Imperial College as a Senior Clinical Lecturer. He was awarded the Action for Pulmonary Fibrosis Mike Bray Fellowship which enabled him to establish his research group studying the interaction between the respiratory tract microbiota and innate immunity in pulmonary fibrosis. He now leads an active clinical and translational research programme, overseeing a multidisciplinary team of basic scientists and clinical trial staff focused on advancing the understanding and treatment of interstitial lung diseases.

Bill is a biopharmaceutical industry advisor with more than 25 years of experience in executive leadership, product development, medical affairs, and board director roles. He is Principal at Teton Bioscience and has provided drug development and strategic advisory services since 2015. He co-founded Indalo Therapeutics, a clinical-stage fibrosis company, served as a Board Director, and was Chief Medical Officer until 2020. He also served as Senior Vice President, Clinical Development at InterMune, Inc. (acquired by Roche) where he led the successful development of Esbriet® for Idiopathic Pulmonary Fibrosis and advanced a product development portfolio spanning a range of therapeutic areas. Earlier in his career, Bill held product development positions at Genentech (part of the Roche Group) and IntraBiotics Pharmaceuticals, and was an infectious disease specialist and researcher at the University of California San Francisco (UCSF). He currently serves on the Board of Directors at Endeavor BioMedicines and the Bluefield Project, recently served on the Boards of Virion Therapeutics and Hennepin Life Sciences, and is a member of multiple scientific advisory boards. Bill received his MD from the University of North Carolina School of Medicine and has a doctorate in epidemiology from University of California, Berkeley. Bill completed his internal medicine residency and infectious disease fellowship at UCSF.

Paul Ford, MD, PhD, is a UK-trained pulmonologist and drug development leader with deep expertise in translational medicine and fibrosis. He spent 10 years at Imperial College London in the laboratory of Prof. Sir Peter Barnes, leading his own research group focused on clinical translational studies in COPD. He also ran the specialist cough service and co-led the difficult asthma clinic with Prof. Barnes. After transitioning from academia in 2009, Dr. Ford held senior R&D roles across industry, including Translational Medicine Lead at Novartis, Chief Medical Officer at Galecto (Copenhagen), Head of Development and Fibrosis at Galapagos (Mechelen), and Head of Development at PureTech (Boston). He designed and led the first-in-human and early clinical programmes for multiple key assets, including GB0139 (Galecto), ziritaxestat and GLPG1205 (Galapagos), and LYT-100 (PureTech). He has overseen IPF trials involving nearly 2,000 patients, such as ISABELA 1 & 2, PINTA, and ELEVATE. Dr. Ford serves as a fractional CMO to several biotech companies, providing strategic and operational leadership across programmes in IPF, AATD, and Alport syndrome. He continues to design and run large registrational Phase 3 trials, as well as early-stage and ATMP-based studies, including secretome, gene therapy, and inhaled therapeutic approaches. He currently oversees a portfolio of > ten development programmes spanning discovery to late-stage clinical execution.

Kent is a consultant specialising in Clinical Oncology at West Suffolk NHS Foundation Trust and has experience running early-phase clinical trials, including PROCON (a phase I/II trial evaluating the use of carbogen and nicotinamide in conjunction with radiotherapy in the treatment of patients with high risk prostate cancer) and L-NNA (a phase I clinical trial sponsored by CRUK evaluating L-NNA as a cancer treatment). Kent has a BSc in Biochemistry and an MBBS in Medicine from Imperial College. He has nearly two decades of clinical oncology experience, working as a specialist registrar before qualifying as a consultant after being awarded an MD in Radiation Oncology from UCL.

John graduated from the University Hospital of Wales in 2001 and completed postgraduate training at Barts and The London in 2006. Appointed consultant clinical oncologist at St Bartholomew’s Hospital in 2014, he became Honorary Senior Lecturer at Barts Cancer Institute in 2025. He earned an MD(Res) from UCL in 2018 following radiotherapy research with the NCRI RTQA Group. John is Clinical Director for Thoracic Oncology, Radiotherapy Lead for HCA UK, and Oncology Clinical Lead for the NLCA. He specialises in lung and breast cancers, advanced systemic therapies, and cutting-edge radiotherapy, and is active in research, education, and community cancer initiatives.

Tamera has over 15 years’ experience as a respiratory physician, including serving as Director of Interstitial Lung Disease (ILD) in the Department of Respiratory Medicine at the Royal Prince Alfred Hospital in Sydney. She trained in respiratory medicine at the University of New South Wales in Sydney and served as Clinical Fellow in ILD at the Royal Brompton Hospital in London with Professor Athol Wells, where she earned a PhD in the identification of pulmonary vascular dysfunction in ILD. She currently leads her Pulmonary Fibrosis research group at the University of Sydney. She is the lead investigator for the national Centre of Research Excellence for Pulmonary Fibrosis and Chair of the  Australasian Interstitial Lung Disease Registry.

Claus is a C-suite leader with two decades of transformation and technology experience. With a proven track record of driving strategic planning, differentiation and optimisation, Claus is focused on building, leading and inspiring diverse teams that innovate and collaborate to achieve critical organisational goals. He currently serves as Chief Information and Technology Officer at the University of Texas Medical Centre and Dell Medical School, leading the innovation and technology elements of establishing a new Academic Medical Centre. Claus also hold an advisory role with Lifespace Communities, Inc.. He was awarded a PhD in Computer Science from Aarhus University, holds a Masters in Computer Science and Bachelors in Mathematics.

Xose is an internationally respected healthcare executive working at the intersection of technology and healthcare. With more than 25 years of professional experience, Xose is committed to advancing healthcare innovation and the strategic use of data to empower decision-making in precision medicine. He is currently Head of the Digital Oncology Network at IQVIA, where he leads the Digital Oncology Network, a pan-European initiative connecting 18 major hospitals to create a cutting-edge, federated and consent-driven cancer data ecosystem. Throughout his career, Xose has excelled at solving biological and data puzzles. Most recently, he served as the inaugural Chief Data Officer at the Institut Curie in Paris. Prior to this, his work took him to the European Bioinformatics Institute and later to Thermo Fisher Scientific, where we worked  as a bioinformatics consultant. Xose holds a PhD from the University of Oviedo, in Spain.  

Javier has over 15 years of experience at the intersection of AI, software engineering and healthcare, and is focused on turning foundational research into real-world impact. He was formerly Senior Principal Science Manager at Microsoft and led the Multimodal AI team at Microsoft Health Futures UK, developing and scaling cutting-edge AI systems to improve patient outcomes across radiology, pathology and clinical care. Javier has led projects including InnerEye, assistive AI for cancer treatment, which was deployed across the NHS to accelerate radiotherapy by automating CT scan planning and segmentation, and MAIRA, a multimodal AI agent for radiology report generation. He also led Microsoft’s collaboration with the Mayo Clinic to develop foundation models for personalised medicine. Javier earned his degree in Computer Science from the University of Oviedo and completed his MSc at the University of Cambridge.

David has held several leadership positions in healthcare technology over the past 20 years, including at Lightpoint Medical (acquired by Telix Pharmaceuticals), GE Healthcare and Novartis. He has a proven track record in technology development and commercialisation, from early-stage ventures to successful exits. He received a joint PhD from MIT and Harvard Medical School. David currently serves as a board chairman across a portfolio of medical device and digital health companies.

Dean of the Faculty of Medicine and Professor of Respiratory Medicine at the University Paris-Saclay and Inserm, France, and Director of the French Pulmonary Hypertension Reference Centre at the Assistance Publique Hôpitaux de Paris (AP-HP). Marc is a world-leading lung specialist and researcher who has devoted his career to deciphering the mechanisms of pulmonary arterial hypertension (PAH) and has built one of the world’s largest PH registries. 

Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital, Virginia, and Professor at Virginia Commonwealth University. Steven has served on multiple committees, including US Food and Drug Administration (FDA) advisory boards and steering committees for clinical trials in PH and idiopathic pulmonary fibrosis. He formerly served as Chair of the FDA Anesthesiology and Respiratory Therapy Devices Panel.

Medical Director for the Pulmonary Hypertension Program and Director of Outreach and Education for the Inova Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital, Virginia. Oksana is also an Associate Professor of Clinical Medicine at Georgetown University School of Medicine, Washington DC, and an Associate Clinical Professor of Medicine at the University of Virginia.

Professor of Respiratory Medicine and coordinator of the National Reference Centre for Rare Pulmonary Diseases at the Louis Pradel Hospital and the Claude Bernard University Lyon 1, France. The centre has pioneered the clinical care and research of patients with rare lung disease and is the only centre in France recognised as part of the European Reference Center Network for interstitial lung diseases. Vincent is an investigator and member of the steering committee of numerous clinical trials and also currently serves as Associate Editor of the European Respiratory Journal.

Deputy Director of the Clinic, Chair of Pulmonary Vascular Medicine, and Professor of Pulmonary Vascular Research at the University Hospital Giessen and Marburg. Ardeschir is also a Visiting Professor for Pulmonary Vascular Medicine at Imperial College London and a founding member of the Pulmonary Vascular Research Institute (PVRI).

Consultant Chest Physician and previous Director of the National Pulmonary Hypertension Centre, Royal Papworth Hospital, Cambridge, UK. She was instrumental in the organisation of PH services in the UK, specifically the National Chronic Thromboembolic PH program. Joanna serves on various scientific, educational, international boards and societies as well as holding editorial duties. Her research focuses on translational programmes in PH, concentrating on chronic thromboembolic PH and idiopathic PAH. Joanna is also an Affiliated Associate Professor, University of Cambridge, UK. 

Consultant Pulmonologist and Lead Clinician in Cardiopulmonary Medicine at Imperial College Healthcare NHS Trust, specialising in pulmonary vascular disease, pulmonary embolism, unexplained breathlessness, and exercise physiology. Luke is also a Professor of Practice in Cardiopulmonary Medicine at the National Health and Lung Institute at Imperial College London.